Foghorn Therapeutics/FHTX

$7.94

2.71%
-
1D1W1MYTD1YMAX

About Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-609, a targeted protein degrader, and which is evaluating in a Phase I study in synovial sarcoma.

Ticker

FHTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adrian Gottschalk

Employees

161

Headquarters

Cambridge, United States

FHTX Metrics

BasicAdvanced
$335.2M
Market cap
-
P/E ratio
-$2.47
EPS
3.17
Beta
-
Dividend rate

What the Analysts think about FHTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
73.17% upside
High $20.00
Low $6.00
$7.94
Current price
$13.75
Average price target

FHTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-82.18% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$17.4M
216.36%
Net income
$-14.3M
-51.36%
Profit margin
-82.18%
-84.63%

FHTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 54.65%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.69
-$0.73
-$0.70
-$0.34
-
Expected
-$0.62
-$0.73
-$0.74
-$0.75
-$0.76
Surprise
11.65%
0.69%
-4.76%
-54.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Foghorn Therapeutics stock

Buy or sell Foghorn Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing